The AβCs of Aβ-cleaving proteases

Malcolm A. Leissring

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

The amyloid β-protein (Aβ), which accumulates abnormally in Alzheimer disease (AD), is degraded by a diverse set of proteolytic enzymes. Aβ-cleaving proteases, largely ignored until only recently, are now known to play a pivotal role in the regulation of cerebral Aβ levels and amyloid plaque formation in animal models, and accumulating evidence suggests that defective Aβ proteolysis may be operative in many AD cases. This review summarizes the growing body of evidence supporting the involvement of specific Aβ-cleaving proteases in the etiology and potential treatment of AD. Recognition of the importance of Aβ degradation to the overall economy of Aβ has revised our thinking about the mechanistic basis of AD pathogenesis and identified a novel class of enzymes that may serve as both therapeutic targets and therapeutic agents.

Original languageEnglish (US)
Pages (from-to)29645-29649
Number of pages5
JournalJournal of Biological Chemistry
Volume283
Issue number44
DOIs
StatePublished - Oct 31 2008

Fingerprint

Alzheimer Disease
Peptide Hydrolases
Proteolysis
Serum Amyloid A Protein
Amyloid Plaques
Amyloid
Animals
Animal Models
Degradation
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

The AβCs of Aβ-cleaving proteases. / Leissring, Malcolm A.

In: Journal of Biological Chemistry, Vol. 283, No. 44, 31.10.2008, p. 29645-29649.

Research output: Contribution to journalArticle

Leissring, Malcolm A. / The AβCs of Aβ-cleaving proteases. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 44. pp. 29645-29649.
@article{5fb3954e30c84b50aff43c1ec7b17d59,
title = "The AβCs of Aβ-cleaving proteases",
abstract = "The amyloid β-protein (Aβ), which accumulates abnormally in Alzheimer disease (AD), is degraded by a diverse set of proteolytic enzymes. Aβ-cleaving proteases, largely ignored until only recently, are now known to play a pivotal role in the regulation of cerebral Aβ levels and amyloid plaque formation in animal models, and accumulating evidence suggests that defective Aβ proteolysis may be operative in many AD cases. This review summarizes the growing body of evidence supporting the involvement of specific Aβ-cleaving proteases in the etiology and potential treatment of AD. Recognition of the importance of Aβ degradation to the overall economy of Aβ has revised our thinking about the mechanistic basis of AD pathogenesis and identified a novel class of enzymes that may serve as both therapeutic targets and therapeutic agents.",
author = "Leissring, {Malcolm A.}",
year = "2008",
month = "10",
day = "31",
doi = "10.1074/jbc.R800022200",
language = "English (US)",
volume = "283",
pages = "29645--29649",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "44",

}

TY - JOUR

T1 - The AβCs of Aβ-cleaving proteases

AU - Leissring, Malcolm A.

PY - 2008/10/31

Y1 - 2008/10/31

N2 - The amyloid β-protein (Aβ), which accumulates abnormally in Alzheimer disease (AD), is degraded by a diverse set of proteolytic enzymes. Aβ-cleaving proteases, largely ignored until only recently, are now known to play a pivotal role in the regulation of cerebral Aβ levels and amyloid plaque formation in animal models, and accumulating evidence suggests that defective Aβ proteolysis may be operative in many AD cases. This review summarizes the growing body of evidence supporting the involvement of specific Aβ-cleaving proteases in the etiology and potential treatment of AD. Recognition of the importance of Aβ degradation to the overall economy of Aβ has revised our thinking about the mechanistic basis of AD pathogenesis and identified a novel class of enzymes that may serve as both therapeutic targets and therapeutic agents.

AB - The amyloid β-protein (Aβ), which accumulates abnormally in Alzheimer disease (AD), is degraded by a diverse set of proteolytic enzymes. Aβ-cleaving proteases, largely ignored until only recently, are now known to play a pivotal role in the regulation of cerebral Aβ levels and amyloid plaque formation in animal models, and accumulating evidence suggests that defective Aβ proteolysis may be operative in many AD cases. This review summarizes the growing body of evidence supporting the involvement of specific Aβ-cleaving proteases in the etiology and potential treatment of AD. Recognition of the importance of Aβ degradation to the overall economy of Aβ has revised our thinking about the mechanistic basis of AD pathogenesis and identified a novel class of enzymes that may serve as both therapeutic targets and therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=57649178322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57649178322&partnerID=8YFLogxK

U2 - 10.1074/jbc.R800022200

DO - 10.1074/jbc.R800022200

M3 - Article

C2 - 18723506

AN - SCOPUS:57649178322

VL - 283

SP - 29645

EP - 29649

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 44

ER -